Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain.

abstract：:Cost-effectiveness analysis is a widely used tool to assess the value of healthcare interventions. Our objective was to conduct a systematic review of the literature on the cost effectiveness of pharmacogenomic interventions. We found 11 studies that met our inclusion criteria. The most commonly examined disease was d...

journal_title：Pharmacogenomics

authors： Phillips KA,Van Bebber SL

更新日期：2004-12-01 00:00:00

abstract：:COVID-19 utilizes the ACE2 pathway as a means of infection. Early data on COVID-19 suggest heterogeneity in the severity of symptoms during transmission and infection ranging from no symptoms to death. The source of this heterogeneity is likely multifaceted and may have a genetic component. Demographic and clinical co...

journal_title：Pharmacogenomics

authors： Snyder EM,Johnson BD

更新日期：2020-07-01 00:00:00

abstract：:Abacavir is an effective antiretroviral drug used to treat HIV-1 infection. Approximately 5% of patients treated with abacavir develop a hypersensitivity reaction that requires discontinuation of the drug. In an initial pharmacogenetic study conducted in a predominantly White male population, multiple markers in the h...

journal_title：Pharmacogenomics

authors： Hughes AR,Mosteller M,Bansal AT,Davies K,Haneline SA,Lai EH,Nangle K,Scott T,Spreen WR,Warren LL,Roses AD,CNA30027 Study Team.,CNA30032 Study Team.

更新日期：2004-03-01 00:00:00

abstract：:While antidepressants are widely used to treat mood and anxiety disorders, only half of the patients will respond to antidepressant treatment and only one-third of patients experience a full remission of symptoms. The identification of genetic biomarkers that predict antidepressant-treatment response can improve curre...

journal_title：Pharmacogenomics

authors： Narasimhan S,Lohoff FW

更新日期：2012-03-01 00:00:00

abstract：:Atrial fibrillation (AF) is most common arrhythmia in general population, with increasing trend in mortality and morbidity. Electrophysiological and structural abnormalities, promoting abnormal impulse formation and propagation, lead to this disease. AF catheter ablation is related to a not small percentage of nonresp...

journal_title：Pharmacogenomics

authors： Sardu C,Santamaria M,Paolisso G,Marfella R

更新日期：2015-11-01 00:00:00

abstract：:Human cytochrome P450 (CYP)3A is a major P450 enzyme found in the liver and gastrointestinal tract. It plays an important role in the metabolism of a wide variety of drugs, some endogenous steroids and harmful environmental contaminants. It has been shown that CYP3A alleles encoding enzymes with little or no activity ...

journal_title：Pharmacogenomics

authors： Liu CH,Peck K,Huang JD,Lin MS,Wang CH,Hsu WP,Wang HW,Lee HL,Lai ML

更新日期：2005-10-01 00:00:00

abstract：:Assessing the distinct prevalence or absence of genetic variants associated with differential response to the anticoagulant medication of warfarin in different population groups is actively pursued by pharmacogenomics community. Populations from Arabian Peninsula are underrepresented in such studies. By way of examini...

journal_title：Pharmacogenomics

authors： John SE,Antony D,Eaaswarkhanth M,Hebbar P,Alkayal F,Tuomilehto J,Alsmadi O,Thanaraj TA

更新日期：2017-06-01 00:00:00

abstract：:The second Annual Meeting of the UK Pharmacogenetics and Stratified Medicine Network was held on 28 September 2011 at The Wellcome Trust Conference Centre on the Wellcome Trust Genome Campus at Hinxton, Cambridge, UK. The meeting preceded the annual Pharmacogenomics and Personalized Medicine conference, which was held...

journal_title：Pharmacogenomics

authors： Hall I

更新日期：2012-01-01 00:00:00

abstract：AIMS:Variant alleles of the CYP2C19 gene were recently associated with survival in breast cancer patients on tamoxifen therapy. CYP2C19 is one of the enzymes involved in the metabolism of tamoxifen into active metabolites. We investigated the hypothesis that CYP2C19*2 and *3 variants, known for their lack of enzyme act...

journal_title：Pharmacogenomics

authors： Ruiter R,Bijl MJ,van Schaik RH,Berns EM,Hofman A,Coebergh JW,van Noord C,Visser LE,Stricker BH

更新日期：2010-10-01 00:00:00

abstract：:Aim: Major drawbacks of percutaneous coronary intervention are the high occurrence of repeat revascularization due to restenosis and disease progression. The aim of this study was to find genetic indicators to predict the risk of repeat revascularization. Materials & methods: From April 2015 to June 2016, 143 patients...

journal_title：Pharmacogenomics

authors： Xiang Q,Liu Z,Lu Y,Mao J,Chen S,Zhao X,Zhou S,Xie Q,Wang Z,Mu G,Jiang J,Gong Y,Cui Y

更新日期：2020-01-01 00:00:00

abstract：AIMS:S-1, an oral fluoropyrimidine, contains tegafur, which is converted to 5-fluorouracil mainly by CYP2A6. We evaluated the association between CYP2A6 polymorphisms and treatment outcome in metastatic gastric cancer patients treated with S-1 plus docetaxel. MATERIALS & METHODS:Chemonaive patients received S-1 40 mg/...

journal_title：Pharmacogenomics

authors： Kong SY,Lim HS,Nam BH,Kook MC,Kim YW,Ryu KW,Lee JH,Choi IJ,Lee JS,Park YI,Kim NK,Park SR

更新日期：2009-07-01 00:00:00

abstract：AIM:The present study introduces a simple method for CYP2D6 genotyping that not only determines the heterozygous or homozygous deletions and duplications, but also distinguishes tandem hybrids. MATERIALS & METHODS:Using two commercially available methods, 49 Korean male subjects were genotyped for CYP2D6. The Affymetr...

journal_title：Pharmacogenomics

authors： Kim J,Lee SY,Lee KA

更新日期：2012-06-01 00:00:00

abstract：UNLABELLED:Glutathione S-transferases (GSTs) participate in the detoxification of chemotherapeutic agents. Genetic polymorphisms in GST genes (GSTP1 Ile105Val, copy-number variants of GSTM1 and GSTT1) that lead to diminished enzyme activity have been associated with increased chemotherapeutic treatment benefit in color...

journal_title：Pharmacogenomics

authors： Funke S,Timofeeva M,Risch A,Hoffmeister M,Stegmaier C,Seiler CM,Brenner H,Chang-Claude J

更新日期：2010-01-01 00:00:00

abstract：:RNA splicing is a tightly regulated process. It is essential for gene expression and, therefore, intervenes in every biological phenomenon in mammals. RNA splicing regulation is cell type-specific in such a way that a cellular situation can be characterised by its repertoire of spliced events, the spliceome. Compariso...

journal_title：Pharmacogenomics

authors： Schweighoffer F,Ait-Ikhlef A,Resink AL,Brinkman B,Melle-Milovanovic D,Laurent-Puig P,Kearsey J,Bracco L

更新日期：2000-05-01 00:00:00

abstract：:Chronic fatigue syndrome (CFS) is prevalent, disabling and costly. Despite extensive literature describing the epidemiology and clinical aspects of CFS, it has been recalcitrant to diagnostic biomarker discovery and therapeutic intervention. This is due to the fact that CFS is a complex illness defined by self-reporte...

journal_title：Pharmacogenomics

authors： Vernon SD,Whistler T,Aslakson E,Rajeevan M,Reeves WC

更新日期：2006-03-01 00:00:00

abstract：AIM:This study aims to evaluate the association between the MTRR rs1801394 alone or in interaction with the MTHFR rs1801133 and susceptibility to colorectal cancer (CRC) and its characteristics in Iranian population. Additionally, both a systematic review and meta-analysis were performed to derive a more precise assess...

journal_title：Pharmacogenomics

authors： Haerian MS,Haerian BS,Molanaei S,Kosari F,Sabeti S,Bidari-Zerehpoosh F,Abdolali E

更新日期：2017-07-01 00:00:00

abstract：BACKGROUND & METHODS:Economic evaluation in genomic medicine is an emerging discipline to assess the cost-effectiveness of genome-guided treatment. Here, we developed a pharmaco-economic model to assess whether pharmacogenomic (PGx)-guided warfarin treatment of elderly ischemic stroke patients with atrial fibrillation ...

journal_title：Pharmacogenomics

authors： Mitropoulou C,Fragoulakis V,Bozina N,Vozikis A,Supe S,Bozina T,Poljakovic Z,van Schaik RH,Patrinos GP

更新日期：2015-01-01 00:00:00

abstract：:Large interindividual variation in efficacy and adverse effects of anti-epileptic therapy presents opportunities and challenges in pharmacogenomics. Although the first true association of genetic polymorphism in drug-metabolizing enzymes with anti-epileptic drug dose was reported 10 years ago, most of the findings hav...

journal_title：Pharmacogenomics

authors： Kasperaviciūte D,Sisodiya SM

更新日期：2009-05-01 00:00:00

abstract：:The multi-drug resistant transporter MDR1/P-glycoprotein, the gene product of MDR1, is a glycosylated membrane protein of 170 kDa, belonging to the ATP-binding cassette (ABC) superfamily of membrane transporters. MDR1 was originally isolated from resistant tumor cells as part of the mechanism of multi-drug resistance,...

journal_title：Pharmacogenomics

authors： Sakaeda T,Nakamura T,Okumura K

更新日期：2003-07-01 00:00:00

abstract：:Arylamine N-acetyltransferases (NATs) catalyze the transfer of an acetyl group from acetyl-CoA to arylhydrazines and to arylamine drugs and carcinogens or to their N-hydroxylated metabolites. NAT plays an important role in detoxification and metabolic activation of xenobiotics and was first identified as the enzyme re...

journal_title：Pharmacogenomics

authors： Pompeo F,Brooke E,Kawamura A,Mushtaq A,Sim E

更新日期：2002-01-01 00:00:00

abstract：:In this report, we review the importance of pharmacovigilance in detecting postmarketing adverse drug events and the potential for developing pharmacogenovigilance programs by integrating pharmacogenomics with pharmacovigilance. We propose to start developing such a program in primary healthcare systems that use basic...

journal_title：Pharmacogenomics

authors： Awada Z,Zgheib NK

更新日期：2014-04-01 00:00:00

abstract：:Aim: We investigated if DEPTOR polymorphisms influence metabolic parameters and risk for vascular complications in Type 2 diabetes (T2D) patients. Methods: T2D patients were genotyped for DEPTOR rs7840156, rs2271900 and rs4871827. We built low homology model of DEPTOR to check the position of two investigated substitu...

journal_title：Pharmacogenomics

authors： Klen J,Goričar K,Horvat S,Stojan J,Dolžan V

更新日期：2019-08-01 00:00:00

abstract：:Damage to the heart can result from both traditional chemotherapeutic agents, such as doxorubicin, and newer 'targeted' therapies, such as trastuzumab. This chemotherapeutic cardiotoxicity is potentially life-threatening and necessitates limiting or discontinuing an otherwise-effective cancer treatment. Clinical strat...

journal_title：Pharmacogenomics

authors： Jensen BC,McLeod HL

更新日期：2013-01-01 00:00:00

abstract：:Choline phospholipid metabolism is altered in a wide variety of cancers. The choline metabolite profile of tumors and cancer cells is characterized by an elevation of phosphocholine and total choline-containing compounds. Noninvasive magnetic resonance spectroscopy can be used to detect this elevation as an endogenous...

journal_title：Pharmacogenomics

authors： Glunde K,Serkova NJ

更新日期：2006-10-01 00:00:00

abstract：:The etiology of statin intolerance is hypothesized to be due to genetic variants that impact statin disposition and clearance. We sought to determine whether genetic variants were associated to statin intolerance. The studied cohort consisted of hyperlipidemic participants (n = 90) clinically diagnosed with statin int...

journal_title：Pharmacogenomics

authors： V Willrich MA,Kaleta EJ,Bryant SC,Spears GM,Train LJ,Peterson SE,Lennon VA,Kopecky SL,Baudhuin LM

更新日期：2018-01-01 00:00:00

abstract：AIM:Hemoglobinopathies exhibit a remarkable phenotypic diversity that restricts any safe association between molecular pathology and clinical outcomes. PATIENTS & METHODS:Herein, we explored the role of genes involved in the nitric oxide biosynthesis and signaling pathway, implicated in the increase of fetal hemoglobi...

journal_title：Pharmacogenomics

authors： Chalikiopoulou C,Tavianatou AG,Sgourou A,Kourakli A,Kelepouri D,Chrysanthakopoulou M,Kanelaki VK,Mourdoukoutas E,Siamoglou S,John A,Symeonidis A,Ali BR,Katsila T,Papachatzopoulou A,Patrinos GP

更新日期：2016-03-01 00:00:00

abstract：:Skeletal muscle toxicity is the primary adverse effect of statins. In this review, we summarize current knowledge regarding the genetic and nongenetic determinants of risk for statin induced myopathy. Many genetic factors were initially identified through candidate gene association studies limited to pharmacokinetic (...

journal_title：Pharmacogenomics

authors： Feng Q,Wilke RA,Baye TM

更新日期：2012-04-01 00:00:00

abstract：AIM:Pharmacogenetic landscapes of commonly used antiplatelet drugs, warfarin and clopidogrel have been studied in-depth in many countries. However, there is a paucity of data to understand their patterns in the Arab populations. MATERIALS & METHODS:We analyzed the whole exome sequencing datasets of 100 Qatar individua...

journal_title：Pharmacogenomics

authors： Sivadas A,Sharma P,Scaria V

更新日期：2016-11-01 00:00:00

abstract：:Insulin-sensitizer treatment with metformin is common in polycystic ovary syndrome (PCOS). OCT alleles were investigated in PCOS patients to identify genetic 'bad responders' and 'nonresponders' to metformin including their possible effects on glucose metabolism without treatment. We genotyped eight SNPs in OCT1, OCT2...

journal_title：Pharmacogenomics

authors： Schweighofer N,Lerchbaum E,Trummer O,Schwetz V,Pieber T,Obermayer-Pietsch B

更新日期：2014-02-01 00:00:00

abstract：:The first observations of inherited differences in drug effects in the 1950s led to the recognition of a genetic basis for drug response. With the development of genetics and molecular biology, it became clear that certain drug responses could be associated with specific genetic variations or polymorphisms. There are ...

journal_title：Pharmacogenomics

authors： Ferentz AE

更新日期：2002-07-01 00:00:00